$MDGL

MADRIGAL PHARMACEUTICALS, INC.

Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for metabolic dysfunction-associated steatohepatitis, or MASH. Its first and only approved product is Rezdiffra, a once-daily oral therapy for adults with noncirrhotic MASH and moderate to advanced liver fibrosis. Madrigal sells Rezdiffra in the United States, where it launched in April 2024, and launched the product in Germany in September 2025. It also earns royalties and makes milestone payments under licensing agreements related to the product. Madrigal is developing a MASH pipeline that includes MGL-2086, an oral GLP-1 receptor agonist; ervogastat, an oral DGAT-2 inhibitor; and six preclinical siRNA programs. The company holds licenses to develop, manufacture and commercialize these candidates. Its business also includes clinical trials and research into Rezdiffra and potential combination therapies. Madrigal is headquartered in West Conshohocken, Pennsylvania.

1
1
0
$35.0M
$431K
BAKER BROS. ADVISORS LP
17%
See all $MDGL insider activity →

Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH

Sonic Incytes and Madrigal Pharmaceuticals (MDGL) announced a multi-year partnership to advance non-invasive liver assessment for MASH. Sonic Incytes' Velacur platform will be used to help clinicians assess and risk-stratify patients. The partnership aims to expand the use of non-invasive tests at the point of care, with a focus on gastroenterology, hepatology, and endocrinology settings.

H.C. Wainwright reiterates Madrigal Pharmaceuticals stock rating citing market position

H.C. Wainwright reiterated a Buy rating and $620 price target for Madrigal Pharmaceuticals (MDGL), citing its market position and undervaluation. The company reported strong Q3 2026 results, including $431.3M revenue and $1.83 EPS, exceeding expectations. MDGL's gross profit margin is 90.96%, with 93% revenue growth over the last year.

MDGL sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning MDGL (MADRIGAL PHARMACEUTICALS, INC.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.

Recent MDGL coverage spans financial news, earnings and insider activity.

In the last 30 days, MDGL insiders filed 6 SEC Form 4 transactions — 5 purchases ($35.0M) and 1 sale ($431K). The most active reporter was BAKER BROS. ADVISORS LP with 5 filings. 17% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving MDGL

AlphAI scores every news story that mentions MDGL with an AI model for sentiment and relevance, and aggregates insider trades from MADRIGAL PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MDGL

Score

Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH

Sonic Incytes and Madrigal Pharmaceuticals (MDGL) announced a multi-year partnership to advance non-invasive liver assessment for MASH. Sonic Incytes' Velacur platform will be used to help clinicians assess and risk-stratify patients. The partnership aims to expand the use of non-invasive tests at the point of care, with a focus on gastroenterology, hepatology, and endocrinology settings.

Top insider buys and sells disclosed on Friday

On Friday, insiders made notable trades in US-listed companies. Baker Bros. bought $35M in Madrigal Pharmaceuticals (MDGL) shares, Kinder Morgan's (KMI) CEO bought $15M in stock, and Kennametal's (KMT) CEO acquired $165k in shares. Meanwhile, Royal Caribbean's (RCL) director sold $82M in stock, and Gilead's (GILD) CEO sold $19.7M in shares. InvestingPro analysis suggests some stocks are undervalued or overvalued.

$MDGLMedAI 8/10

BAKER BROS. ADVISORS LP (BAKER FELIX, BAKER JULIAN) purchased $35.0M of MDGL (indirect holdings)

BAKER BROS. ADVISORS LP purchased 91,806 indirectly-held shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at an average of $381.49 ($366.99–$396.61, $35.02M total) across 5 trades over 2026-11-04 to 2026-11-06. Filed jointly with Baker Bros. Advisors (GP) LLC (Director), BAKER FELIX (Director), BAKER JULIAN (Director), 667, L.P. (Director) and Baker Brothers Life Sciences LP (Director).

Related tickers